Evaluation of the Biofield Energy Treated Novel Test Formulation on Overall Organs Health Specific Biomarkers

Journal: Alternative Medicine & Chiropractic Open Access Journal PDF  

Published: June 25, 2019 Volume: 2 Issue: 3

ISSN: 2642-0171

Authors: Suzuki J, Trivedi MK, Branton A, Trivedi D, Nayak G, Mondal SC, and Jana S

Citation: Suzuki J, et al. Evaluation of the Biofield Energy Treated Novel Test Formulation on Overall Organs Health Specific Biomarkers. Alt Med Chiropractic OA J 2019, 2(3): 180021.

  • 87 Views
  • 1 Downloads

Abstract

The aim was to study the impact of the Biofield Energy Treated test formulation on the function of vital organs viz. bones, heart, liver, lungs, and brain in various cell-based assays. The test formulation and the cell media were divided into two parts; one part was untreated (UT) and other part received the Biofield Energy Treatment remotely by a renowned Biofield Energy Healer, John Suzuki, USA and was labeled as the Biofield Energy Treated (BT) test formulation/media. Cell viability data suggested that the test formulation was safe and non-toxic in nature in six different cells. The Biofield Treated medium (BT-Med) + Biofield Treated Test Item (BT-TI) group showed 91.6%, 56.9%, and 114.5% restoration of cell viability at 1, 10, and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UTTI group. Moreover, BT-Med + BT-TI group showed 70.6%, 126.3%, and 60.2% restoration of cell viability at 1, 25, and 63 µg/mL, respectively; while 78.5% in the UT-Med + BT-TI group in human hepatoma cells (HepG2) compared to untreated. Furthermore, 72.6% (at 0.1 µg/mL), 57.4% (at 25 µg/mL), and 90.4% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + UT-TI, UT-Med + BT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated. The alkaline phosphatase (ALP) level was significantly increased by 82.2% and 106.6% in the UT-Med + BT-TI and BT-Med + UT-TI groups, respectively at 10 µg/mL; while 80.2% (at 10 µg/mL) in the BT-Med + BT-TI group in human bone osteosarcoma cells (MG-63) compared to the untreated. Additionally, the level of ALP was significantly increased by 90.2% (at 0.1 µg/mL) and 78.3% (at 10µg/mL) in the BT-Med + BT-TI group in human endometrial adenocarcinoma cells (Ishikawa) compared to the untreated. The percent protection of HCF (heart) cells (decreased of LDH activity) was significantly increased by 63.7%, 59.6%, and 63.3% at 1, 10, and 25 µg/mL, respectively in the BT-Med + BT-TI group; while 122.2% (at 0.1 µg/mL) in the UT-Med + BT-TI group as compared to the untreated in HCF cells. The percent protection of HepG2 (liver) cells (decreased of ALT activity) was significantly increased by 62.8% and 153.2% at 1 µg/mL in the UT-Med + BT-TI and BT-Med + BT-TI groups, respectively compared to untreated in HepG2 cells. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 133.1%, 153.8%, and 107.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BTMed + BT-TI groups, respectively at 10 µg/mL compared to untreated. Serotonin level was significantly increased by 75.7% (at 10 µg/mL), 124.1% (at 10 µg/mL), and 73.5% (at 10 µg/mL) in the BT-Med + UT-TI group at 10, 25, and 63 µg/mL, respectively; while 107.7% (at 25 µg/mL) in the BT-Med + BT-TI group as compared to the untreated in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptor (VDR) was significantly increased by 162.2% (at 10 µg/mL), 193.3% (at 1 µg/mL), and 148.7% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated in MG-63 cells. Overall, these results suggest that Biofield Treated test formulation significantly improved the bones, heart, liver, lungs, and brain functional enzyme biomarkers. Altogether data suggest that the Biofield Energy Treatment (The Trivedi Effect®) can be useful to protect and maintain the normal function of each vital organ such as lungs, liver, heart, brain, and bones. Therefore, The Trivedi Effect® can be used as a complementary and alternative therapy against several disorders such as coronary artery disease, heart attack, heart failure, arrhythmias, congenital heart disease, cirrhosis, cardiomyopathy, Wilson disease, liver cancer, hemochromatosis, pneumonia, asthma, cystic fibrosis, emphysema, chronic bronchitis, osteoporosis, etc.

Conclusion

The study findings showed that the tested novel test formulation was safe and non-toxic based on MTT cell viability assay in six tested cells. BT-Med + BT-TI group showed 91.6% and 114.5% restoration of cell viability at 1 and 25 µg/mL, respectively in human cardiac fibroblasts cells (HCF) compared to the UT-Med + UT-TI group. Moreover, the BT-Med + BT-TI group showed 70.6% and 126.3% restoration of cell viability at 1 and 25 µg/mL, respectively while 78.5% in the UT-Med + BT-TI group in human hepatoma cells (HepG2) compared to the untreated group. Additionally, 72.6% (at 0.1 µg/mL) and 90.4% (at 63 µg/mL) restoration of cell viability was observed in adenocarcinomic human alveolar basal epithelial cells (A549) by BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated. Alkaline phosphatase (ALP) activity was significantly increased by 82.2% and 106.6% in the UT-Med + BT TI and BT-Med + UT TI groups, respectively at 10µg/mL in human bone osteosarcoma cells (MG-63). Moreover, ALP activity was significantly increased by 90.2% in the BTMed + BT-TI group at 0.1µg/mL than untreated group. The percent protection of HCF cells (decreased of LDH activity) was significantly increased by 122.2% (at 0.1µg/mL) in the UT-Med + BT-TI group compared to the untreated. The percent protection of HepG2 cells (decreased of ALT activity) was significantly increased by 153.2% at 1 µg/mL in the BT-Med + BT-TI group compared to the untreated group. The percent protection of A549 (lungs) cells (increased of SOD activity) was significantly increased by 133.1%, 153.8%, and 107.5% in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BTTI groups, respectively at 10 µg/mL compared to the untreated group. The serotonin level was significantly increased by 124.1% (at 10µg/mL) and 107.7% (at 25µg/mL) in the BT-Med + UT-TI and BT-Med + BT-TI groups, respectively compared to the untreated group in human neuroblastoma cells (SH-SY5Y). The relative quantification (RQ) of vitamin D receptors (VDRs) level was significantly increased by 162.2% (at 10 µg/mL), 193.3% (at 1µg/mL), and 148.7% (at 0.01 µg/mL) in the UT-Med + BT-TI, BT-Med + UT-TI, and BT-Med + BT-TI groups, respectively compared to the untreated group in MG-63 cells. In conclusion, the Biofield Energy Treatment significantly improved heart, liver, bones, neuronal, and lungs functional enzyme biomarkers and also protected cardiomyocyte, hepatocyte, osteocytes, pneumocyte, and nerve cells from oxidative damage induced by tert-butyl hydroperoxide (t-BHP). Thus, results suggested that Biofield Energy Treatment can be used as a complementary and alternative treatment for the prevention of various types of cardiac disorders (peripheral artery disease, high blood pressure, congenital heart disease, stroke, congestive heart failure, rheumatic heart disease, carditis, valvular heart disease, thromboembolic disease, and venous thrombosis, etc.), hepatic disorders (cirrhosis, Wilson disease, liver cancer, hemochromatosis), and lungs disorders (Asthma, Emphysema, Chronic bronchitis, Pneumonia, Cystic fibrosis). Further, it can be useful to improve cell-to-cell messaging, normal cell growth and differentiation, cell cycling and proliferation, neurotransmission, skin health, hormonal balance, immune and cardiovascular functions. Moreover, it can also be utilized in organ transplants (i.e., liver, kidney, and heart transplants), , aging, hormonal imbalance and various inflammatory and immune-related disease conditions like Alzheimer’s Disease (AD), Dermatitis, Asthma, Ulcerative Colitis (UC), Hashimoto Thyroiditis, Pernicious Anemia, Sjogren Syndrome, Aplastic Anemia, Multiple Sclerosis, Hepatitis, Graves’ Disease, Irritable Bowel Syndrome (IBS), Dermatomyositis, Diabetes, Myasthenia Gravis, Atherosclerosis, Parkinson’s Disease, Systemic etc. to Lupus Erythematosus (SLE), stress, improve overall health and Quality of Life.